Singular Genomics Completes Acquisition by Deerfield Management
Singular Genomics Systems, Inc. (Nasdaq: OMIC), specializing in next-generation sequencing and spatial multiomics technologies, has officially completed its acquisition by an affiliate of Deerfield Management Company. This significant move is set to create more substantial opportunities for advancements in genomic research and clinical applications.
Details of the Acquisition Agreement
Previously, on December 23, 2024, Singular Genomics announced a definitive agreement allowing Deerfield to acquire all outstanding shares of its common stock for a cash consideration of $20.00 per share. This acquisition comes after satisfying several customary conditions, including a vote for approval by the shareholders of Singular Genomics that happened recently.
Transitioning to a Private Company
The transaction successfully closed on February 19, 2025, resulting in Singular Genomics transitioning into a private company. Such a shift is anticipated to provide the company with enhanced flexibility to pursue its strategic goals more efficiently. Following this transaction, trading of its common stock on Nasdaq has been suspended, and efforts are underway to delist the company’s stock from the exchange.
Leadership Changes and Future Directions
As part of the acquisition, Singular Genomics has welcomed Josh Stahl as its new Chief Executive Officer, who will also join the Board of Directors. Also joining the board is Jason Myers, while Drew Spaventa, the company’s co-founder and former CEO, will continue to serve on the Board, taking on additional responsibilities as a special advisor to the CEO. This new leadership structure is expected to steer Singular Genomics into a new era of growth and innovation.
Commitment to Advanced Technology
Andrew ElBardissi, M.D., a partner at Deerfield, expressed enthusiasm for supporting Singular Genomics through this transitional phase, highlighting a dedication to advancing technology in the genomic field. The collaboration aims to leverage Singular’s innovative capabilities in sequencing and multiomics.
The Importance of Multiomics
Singular Genomics is committed to empowering researchers and healthcare professionals by providing essential information derived from sequencing and multiomics. Their commercially available G4 Sequencing Platform exemplifies this commitment, designed to deliver rapid and precise genomic results.
Future Innovations: G4X™ Spatial Sequencer
In addition to the G4 platform, Singular Genomics is actively working on the G4X™ Spatial Sequencer. This innovative technology aims to utilize proprietary sequencing protocols to facilitate in situ readouts for transcriptomics and proteomics, among other applications. This development aims to advance scientific research considerably while maintaining a spatial context of the data.
Dedicated Advisors for the Transition
The transition has been supported by a team of advisors. TD Securities and Houlihan Lokey acted as financial advisors for the Singular Genomics Board's Special Committee, while Gunderson Dettmer, LLP provided legal counsel. Richards, Layton & Finger, P.A. served as counsel for the Special Committee, and Katten Muchin Rosenman LLP represented Deerfield during the acquisition.
Contact Information for Investors and Media
For further inquiries, investors are encouraged to reach out to Philip Trip Taylor at Gilmartin Group via email at ir@singulargenomics.com. For media-related questions, Matt Browning can be contacted at pr@singulargenomics.com. These contacts are crucial for keeping stakeholders informed during this transformative phase for Singular Genomics.
Frequently Asked Questions
What does the acquisition mean for Singular Genomics?
The acquisition allows Singular Genomics to operate as a private company, providing greater flexibility to pursue its strategic initiatives and innovate further in the field of genomic technologies.
Who is the new CEO of Singular Genomics?
Josh Stahl has been appointed as the new Chief Executive Officer as part of the leadership transition following the acquisition.
What is the G4X™ Spatial Sequencer?
The G4X™ Spatial Sequencer is an advanced technology being developed by Singular Genomics aimed at improving in situ readouts for various genomic analysis applications, enhancing scientific research capabilities.
What changes are expected in the company’s operations?
Transitioning to a private company is expected to streamline operations and focus on advanced technological developments without the pressures associated with being publicly traded.
How can investors reach out for more information?
Investors can contact Philip Trip Taylor at Gilmartin Group by emailing ir@singulargenomics.com for more information on the company and its future directions.
